Navigation Links
Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
Date:4/1/2008

Leading Expert Discusses Study During Late-Breaking Presentations at ACC

CHICAGO, April 1, 2008 /PRNewswire/ -- Final six-month, follow-up patient data presented today during the late-breaking clinical trial sessions at the American College of Cardiology, suggest MyoCell(R) myoblast clinical cell therapy is a safe and potentially effective alternative treatment to standard medical therapy alone for improving heart function among patients with previously implanted cardiac devices who are experiencing congestive heart failure.

The findings from the SEISMIC(1) Trial, a 40-patient, randomized, multicenter, controlled, Phase II-a study conducted in Europe, evaluated MyoCell myoblast clinical cell therapy delivered via the MyoCath(R), endoventricular needle-injection catheter in patients previously fitted with implanted cardiac defibrillators(ICDs), receiving standard medical therapy and who are experiencing congestive heart failure. On admission to the trial, patients were randomized on a two-to-one ratio into the treatment versus control groups with 26 patients receiving MyoCell therapy and 14 patients in the control group. All patients were experiencing congestive heart failure and were previously fitted with ICDs and receiving standard medical therapy. Both the MyoCell biologic therapy and the MyoCath needle-injection catheter, developed by Bioheart, Inc., are currently being studied as investigational products.

"The results from the SEISMIC Trial are encouraging," said Prof. Patrick W. Serruys, MD, PhD, Principal Investigator and Chief, Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center - Rotterdam, the Netherlands. "While the study was specifically designed to show safety, the findings also suggest positive trends in clinical benefits when evaluating the treated group versus the control group at six months."

Patients in both groups were evaluated at three- and six-month intervals using a variety of tests, i
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
3. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
4. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
5. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
6. Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
7. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
8. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... and BEDFORD, Mass. , ... Arroyo LLP is investigating whether certain officers ... Securities and Exchange Act of 1934.  ConforMIS is a ... platform to develop, manufacture, and sell joint replacement implants ... patient,s unique anatomy. View this press release ...
(Date:9/1/2015)... Delaware , United States ... "Company" or "Invion"), is pleased to announce that it has ... an institutional investor in the United States ... approximately A$1.001 million ("Placement") by the issue of 71,500,000 million ... per share. The Company has also agreed ...
(Date:9/1/2015)... and OR YEHUDA, Israel , Sept. ... HTWR ), a leading innovator of less invasive, ... of advanced heart failure, announced today that it has ... Cardio, Ltd . ("Valtech").  Valtech is a privately held ... and transcatheter valve repair and replacement devices for the ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
... 2011 Visionary Pharmaceuticals, Inc., announced today that ... a consortium of Angel Investors. The company is ... retinoic acid related orphan receptor (ROR) modulators targeting ... disorders including rheumatoid arthritis, multiple sclerosis, psoriasis and ...
... Ind., July 26, 2011 Symmetry Medical Inc. (NYSE: ... the global orthopaedic device industry and other medical markets, announced ... for the period ending July 2, 2011 before the market ... an accompanying conference call at 8:00 a.m. ET on Thursday, ...
Cached Medicine Technology:Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities 2Symmetry Medical to Report Second Quarter 2011 Financial Results on August 4, 2011 2
(Date:9/2/2015)... , ... September 02, 2015 , ... Ericson is a ... Education Director for HCPro and Associate Director of Education for the Association for Clinical ... CDI and ICD-10 for CDI Boot Camps. She serves as a CDI subject matter ...
(Date:9/2/2015)... ... ... Every year at this time, students prepare to go back to school. ... the academic workload confronting them. They just don’t have the skills needed to do ... students how to study. , “Bankers bank. Salesmen sell. Teachers teach. The job of ...
(Date:9/2/2015)... City, KS (PRWEB) , ... September 02, 2015 , ... ... opened its newest office in Kansas – its Johnson County location. Amada ... in healthcare. Mike has a registered nurse background and spent over 20 years in ...
(Date:9/2/2015)... North Las Vegas, NV (PRWEB) , ... September ... ... in Las Vegas and Fort Lauderdale, CENTURION SERVICE GROUP is internationally known as ... the largest medical auction house in the world, selling more than 100,000 pieces ...
(Date:9/2/2015)... ... 02, 2015 , ... On September 9, 2015, over 27,000 people from all ... single-company convention to date for the state of Utah. , “We are thrilled with ... states David Stirling, doTERRA CEO. “One of the most exciting elements of our convention ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2
... Dec. 1 The Kerlan Jobe Orthopaedic Clinic, a sports ... United States $3 million to settle allegations that it received ... , The settlement resolves allegations ... of stock option grants, donations to the Kerlan Jobe Foundation, ...
... A scientist who broadened the understanding of how we experience ... -- has won the 2010 University of Louisville Grawemeyer Award ... University in Montreal, was selected for the award from among ... of injury but instead in their brain through a pathway ...
... more likely, British study finds , TUESDAY, Dec. 1 (HealthDay ... to deliver a very preterm baby than more affluent women, ... British study shows. , The University of Leicester research team ... the association between economic status and preterm birth. , For ...
... on computed tomography (CT) imaging of changes in tumors ... bevacizumab may have the potential to predict overall survival, ... of JAMA . The addition of ... with improved survival in patients with stage IV colorectal ...
... ... ... largest national HIV non-profit organizations, is changing its name to HealthHIV and launching a new ... promote the organization’s new vision and expanded capabilities and reach. , , , , ,“HealthHIV ...
... With employee benefit choices becoming more complex, a growing ... during open enrollment season, according to a new survey by ... employers who offer these tools believe they lead employees to ... survey, 45 percent of companies offered employees self-service decision tools ...
Cached Medicine News:Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2Health News:Scientist Who Helps Explain Pain Wins Grawemeyer Award 2Health News:More Preemies Born Among the Poor 2Health News:Criteria based on CT imaging after chemotherapy may help predict survival 2Health News:National HIV Non-Profit Announces New Name 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: